Rolapitant Hydrochloride Hydrate Intermediate CAS 1214741-14-6 Purity >98.0% (HPLC)
Ruifu Chemical is the leading manufacturer of Rolapitant Hydrochloride Hydrate Intermediate (CAS: 1214741-14-6) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase Rolapitant Hydrochloride Hydrate Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | (S)-1-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-2-Phenylbut-3-en-2-Amine Fumarate |
| Synonyms | Rolapitant Int 2; Rolapitant Intermediate 2; (S)-1-((R)-1-(3,5-Bis(trifluoroMethyl)phenyl)ethoxy)-2-Phenylbut-3-en-2-Amine Maleic Acid; (alphaS)-alpha-[[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]methyl]-alpha-Ethenylbenzenemethanamine Monomaleate |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 1214741-14-6 |
| Molecular Formula | C20H19F6NO.C4H4O4 |
| Molecular Weight | 519.43 g/mol |
| Storage Temp. | Under Inert Gas (Nitrogen or Argon) at 2~8℃ |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | White or Off-White Powder | Complies |
| Water by Karl Fischer | <0.50% | 0.08% |
| Purity / Analysis Method | >98.0% (HPLC) | 99.2% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Rolapitant Hydrochloride Hydrate (CAS: 914462-92-3) | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from exposure to light and moisture, avoid fire.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
(S)-1-((R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-2-Phenylbut-3-en-2-Amine Fumarate (CAS: 1214741-14-6) is an intermediate of Rolapitant Hydrochloride Hydrate (CAS: 914462-92-3). Rolapitant Hydrochloride Hydrate, originally discovered by Schering-Plough and later developed by TESARO, Inc., was approved by the FDA in September 2015 for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in combination with other antiemetic agents. Rolapitant is a highly selective NK-1 receptor antagonist, exhibiting >1000- fold selectivity for NK-1 over human NK-2 and NK-3 receptors in vitro. In contrast to other NK-1 inhibitors that play an essential role in delayed CINV therapy, rolapitant shows no inhibition of CYP3A4, eliminating the need for concern when coadministering with CYP34A substrates. Additionally, rolapitant is an orally active agent with a relatively long half-life (180 h), providing potential opportunities for single- and prechemotherapy-based treatments. In three large clinical trials involving patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC), subjects using rolapitant as a cotherapy with granisetron and dexamethasone showed a significant improvement in complete response compared to those receiving treatments of granisetron and dexamethasone.
